STOCK TITAN

[SCHEDULE 13G] CASTLE BIOSCIENCES INC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Dimensional Fund Advisors LP reported beneficial ownership of 1,474,089 shares of Castle Biosciences Inc common stock, representing 5.1% of the class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership while reporting sole voting power over 1,447,712 shares and sole dispositive power over 1,474,089.

The Schedule 13G indicates the position is held in the ordinary course of business and not to influence control of the issuer. The filing was signed by Dimensional's Global Chief Compliance Officer on 10/09/2025.

Dimensional Fund Advisors LP ha riferito la proprietà benefica di 1,474,089 azioni ordinarie di Castle Biosciences Inc, che rappresentano 5,1% della categoria. L'atto riporta che queste azioni sono detenute da fondi comuni consigliati o sub‑consigliati da Dimensional e che Dimensional rinuncia a ogni diritto di proprietà benefica pur riferendo potere di voto esclusivo su 1,447,712 azioni e potere dispositivo esclusivo su 1,474,089.

Lo Schedule 13G indica che la posizione è detenuta nell'ambito normale dell'attività e non per influenzare il controllo dell'emittente. L'atto è stato firmato dal Global Chief Compliance Officer di Dimensional in data 10/09/2025.

Dimensional Fund Advisors LP reportó la propiedad beneficiosa de 1,474,089 acciones comunes de Castle Biosciences Inc, que representan el 5.1% de la clase. El archivo indica que estas acciones son propiedad de fondos de inversión asesorados o subasesorados por Dimensional y que Dimensional renuncia a la titularidad beneficiosa mientras reporta poder de voto exclusivo sobre 1,447,712 acciones y poder dispositvo exclusivo sobre 1,474,089.

El Schedule 13G indica que la posición se mantiene en el curso normal de los negocios y no para influir en el control del emisor. El archivo fue firmado por el Chief Compliance Officer Global de Dimensional el 09/10/2025.

Dimensional Fund Advisors LP가 Castle Biosciences Inc 일반주식 1,474,089주에 대한 유익한 소유를 보고했으며, 이는 해당 등급의 5.1%를 차지합니다. 공시는 이 주식이 Dimensional이 자문 또는 하자문을 받는 투자펀드의 소유이며, Dimensional은 유익한 소유권을 부인하지만 1,447,712주에 대해 단독 의결권과 1,474,089주에 대해 단독 처분권을 보고합니다.

Schedule 13G은 이 포지션이 발행인의 통제를 목표로 하지 않고 일반 업무상으로 보유되었음을 나타냅니다. 이 서류는 Dimensional의 글로벌 최고 컴플라이언스 책임자에 의해 2025-10-09에 서명되었습니다.

Dimensional Fund Advisors LP a déclaré une propriété bénéficiaire de 1 474 089 actions ordinaires de Castle Biosciences Inc, représentant 5,1% de la catégorie. Le dossier indique que ces actions sont détenues par des fonds d'investissement conseillés ou sous‑conseillés par Dimensional et que Dimensional décline toute propriété bénéficiaire tout en indiquant un pouvoir de vote exclusif sur 1 447 712 actions et un pouvoir discrétionnaire exclusif sur 1 474 089.

Le Schedule 13G indique que la position est détenue dans le cours normal des affaires et non pour influencer le contrôle de l'émetteur. Le dépôt a été signé par l'agent mondial de conformité de Dimensional le 09/10/2025.

Dimensional Fund Advisors LP meldete einen wirtschaftlichen Eigentum an 1.474.089 Stammaktien der Castle Biosciences Inc, was 5,1% der Klasse entspricht. Die Einreichung besagt, dass diese Aktien von Investmentfonds gehalten werden, die von Dimensional beraten oder unterberaten werden, und dass Dimensional kein wirtschaftliches Eigentum geltend macht, während es alleinige Stimmenmacht über 1.447.712 Aktien und alle dispositiven Macht über 1.474.089 berichtet.

Der Schedule 13G gibt an, dass die Position im normalen Geschäftsgang gehalten wird und nicht dazu dient, die Kontrolle des Emittenten zu beeinflussen. Die Einreichung wurde von Dimensional's Global Chief Compliance Officer am 10.09.2025 unterzeichnet.

أعلنت Dimensional Fund Advisors LP عن امتلاك فعّال لـ 1,474,089 سهماً من أسهم Castle Biosciences Inc العادية، تمثل 5.1% من الفئة. وتذكر الوثيقة أن هذه الأسهم مملوكة من قبل صناديق استثمارية موصى بها أو مُشار إليها من Dimensional وأن Dimensional تتنصل من الملكية الفعّالة مع الإبلاغ عن سلطة التصويت الحصرية على 1,447,712 سهماً والسلطة التصرفية الحصرية على 1,474,089.

يشير Schedule 13G إلى أن الوضعية تُحتفظ بها في سياق الأعمال الاعتيادي وليس للتأثير في سيطرة المصدر. وقد وقع على الملف من قِبل كبير مسؤولي الامتثال العالمي في Dimensional في 10/09/2025.

Dimensional Fund Advisors LP 报告对 Castle Biosciences Inc 普通股拥有 1,474,089 股,代表该类别的 5.1% 该申报指出这些股份由 Dimensional 劝导或辅助投资的基金所持有,Dimensional 免责声明作出受益所有权,但就 1,447,712 股拥有单独表决权、对 1,474,089 股拥有单独处置权。

Schedule 13G 表示该头寸是在正常经营过程中持有的,而非为影响发行人的控制。该申报由 Dimensional 的全球合规总监在 2025-10-09 签署。

Positive
  • Material disclosure of 1,474,089 shares ( 5.1% ) provides transparency to investors
  • Clear certification that the position is held in the ordinary course of business and not to influence control
Negative
  • Dimensional disclaims beneficial ownership while reporting voting/dispositive power, which may limit clarity on ultimate economic ownership
  • Passive status (Schedule 13G) means no stated engagement with issuer governance despite a >5% stake

Insights

Dimensional holds a passive but material 5.1% stake via managed funds.

The position of 1,474,089 shares equals a modest, reportable stake that meets the >5% disclosure threshold and is reported on Schedule 13G, which typically signals a passive investment rather than an intent to change control.

This holding gives Dimensional sole voting power over 1,447,712 shares while it disclaims beneficial ownership because the securities are owned by the Funds it advises. Monitor any future amendments or Schedule 13D filings for changes in intent or increased ownership.

Filing reflects standard adviser reporting and compliance certification.

The form identifies Dimensional as an investment adviser and contains the certification that the shares are held in the ordinary course of business and not to influence issuer control. The signature by the Global Chief Compliance Officer completes the required attestation.

Regulatory items to watch include any shift from Schedule 13G to Schedule 13D or material changes in voting/dispositive power; the current filing documents the passive status as of 10/09/2025.

Dimensional Fund Advisors LP ha riferito la proprietà benefica di 1,474,089 azioni ordinarie di Castle Biosciences Inc, che rappresentano 5,1% della categoria. L'atto riporta che queste azioni sono detenute da fondi comuni consigliati o sub‑consigliati da Dimensional e che Dimensional rinuncia a ogni diritto di proprietà benefica pur riferendo potere di voto esclusivo su 1,447,712 azioni e potere dispositivo esclusivo su 1,474,089.

Lo Schedule 13G indica che la posizione è detenuta nell'ambito normale dell'attività e non per influenzare il controllo dell'emittente. L'atto è stato firmato dal Global Chief Compliance Officer di Dimensional in data 10/09/2025.

Dimensional Fund Advisors LP reportó la propiedad beneficiosa de 1,474,089 acciones comunes de Castle Biosciences Inc, que representan el 5.1% de la clase. El archivo indica que estas acciones son propiedad de fondos de inversión asesorados o subasesorados por Dimensional y que Dimensional renuncia a la titularidad beneficiosa mientras reporta poder de voto exclusivo sobre 1,447,712 acciones y poder dispositvo exclusivo sobre 1,474,089.

El Schedule 13G indica que la posición se mantiene en el curso normal de los negocios y no para influir en el control del emisor. El archivo fue firmado por el Chief Compliance Officer Global de Dimensional el 09/10/2025.

Dimensional Fund Advisors LP가 Castle Biosciences Inc 일반주식 1,474,089주에 대한 유익한 소유를 보고했으며, 이는 해당 등급의 5.1%를 차지합니다. 공시는 이 주식이 Dimensional이 자문 또는 하자문을 받는 투자펀드의 소유이며, Dimensional은 유익한 소유권을 부인하지만 1,447,712주에 대해 단독 의결권과 1,474,089주에 대해 단독 처분권을 보고합니다.

Schedule 13G은 이 포지션이 발행인의 통제를 목표로 하지 않고 일반 업무상으로 보유되었음을 나타냅니다. 이 서류는 Dimensional의 글로벌 최고 컴플라이언스 책임자에 의해 2025-10-09에 서명되었습니다.

Dimensional Fund Advisors LP a déclaré une propriété bénéficiaire de 1 474 089 actions ordinaires de Castle Biosciences Inc, représentant 5,1% de la catégorie. Le dossier indique que ces actions sont détenues par des fonds d'investissement conseillés ou sous‑conseillés par Dimensional et que Dimensional décline toute propriété bénéficiaire tout en indiquant un pouvoir de vote exclusif sur 1 447 712 actions et un pouvoir discrétionnaire exclusif sur 1 474 089.

Le Schedule 13G indique que la position est détenue dans le cours normal des affaires et non pour influencer le contrôle de l'émetteur. Le dépôt a été signé par l'agent mondial de conformité de Dimensional le 09/10/2025.

Dimensional Fund Advisors LP meldete einen wirtschaftlichen Eigentum an 1.474.089 Stammaktien der Castle Biosciences Inc, was 5,1% der Klasse entspricht. Die Einreichung besagt, dass diese Aktien von Investmentfonds gehalten werden, die von Dimensional beraten oder unterberaten werden, und dass Dimensional kein wirtschaftliches Eigentum geltend macht, während es alleinige Stimmenmacht über 1.447.712 Aktien und alle dispositiven Macht über 1.474.089 berichtet.

Der Schedule 13G gibt an, dass die Position im normalen Geschäftsgang gehalten wird und nicht dazu dient, die Kontrolle des Emittenten zu beeinflussen. Die Einreichung wurde von Dimensional's Global Chief Compliance Officer am 10.09.2025 unterzeichnet.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Dimensional Fund Advisors LP
Signature:Selwyn Notelovitz
Name/Title:Global Chief Compliance Officer
Date:10/09/2025

FAQ

What stake does Dimensional Fund Advisors hold in Castle Biosciences (CSTL)?

Dimensional reports beneficial ownership of 1,474,089 shares, representing 5.1% of the common stock.

Does Dimensional have voting power over the CSTL shares?

Yes. The filing reports sole voting power over 1,447,712 shares and sole dispositive power over 1,474,089 shares.

Are the shares owned directly by Dimensional Fund Advisors?

No. The shares are owned by funds advised or sub‑advised by Dimensional; Dimensional disclaims direct beneficial ownership.

Was this position reported as passive or active?

The position is reported on Schedule 13G with a certification that the shares are held in the ordinary course of business and not to influence issuer control, indicating passive intent.

When was the Schedule 13G signed?

The filing was signed by the Global Chief Compliance Officer on 10/09/2025.
Castle Biosciences

NASDAQ:CSTL

CSTL Rankings

CSTL Latest News

CSTL Latest SEC Filings

CSTL Stock Data

686.34M
28.17M
2.9%
93.07%
5.23%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD